Financial Toxicity

The economic burden faced by patients with cancer who have low income may be more pervasive than previously thought. According to data presented at the 2019 ASCO Quality Care Symposium, even patients enrolled in clinical trials are at high risk for financial toxicity. Read More ›

  • Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
  • Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda Advanced Head and Neck Cancers
  • Discussing Costs of Genomic Testing with Patients
Read More ›

The economic burden caused by cancer and its treatment affects more than the patient’s bank account. As studies have shown, financial toxicity can lead to reduced quality of life, compromise treatment, and worsen clinical outcomes, and the associated devastation can extend to caregivers as well. Read More ›


Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics. Read More ›

With healthcare premiums on the rise and out-of-pocket costs skyrocketing, almost every person diagnosed with cancer is at risk for being underinsured, but this threat extends beyond a patient’s bank balance. Read More ›

As the cost of cancer care continues to rise, greater transparency throughout the process of drug pricing and drug payment needs to become part of the clinical discussion, said Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. Read More ›



Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: